Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma

Jin, G.; Chang, Y.; Bao, X.

doi:10.1016/j.iotech.2023.100409

Cited by 7 publications

(1 citation statement)

References 27 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human settings, the THP-1 cell line, a macrophage/monocyte derivative, has been utilized (170,171). Macrophages can also be induced from hematopoietic stem and progenitor cells (172)(173)(174)(175)(176), human pluripotent stem cells (177), and iPSCs (175,(178)(179)(180). In addition, there is interest in the in-situ generation of CAR macrophages using nanoparticles as well (181)(182)(183)(184).…”

Section: Properties and Advantagesmentioning

confidence: 99%

CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy

Huang,

Yang,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy. However, significant challenges limit its application beyond B cell-driven malignancies, including limited clinical efficacy, high toxicity, and complex autologous cell product manufacturing. Despite efforts to improve CAR T cell therapy outcomes, there is a growing interest in utilizing alternative immune cells to develop CAR cells. These immune cells offer several advantages, such as major histocompatibility complex (MHC)-independent function, tumor microenvironment (TME) modulation, and increased tissue infiltration capabilities. Currently, CAR products from various T cell subtypes, innate immune cells, hematopoietic progenitor cells, and even exosomes are being explored. These CAR products often show enhanced antitumor efficacy, diminished toxicity, and superior tumor penetration. With these benefits in mind, numerous clinical trials are underway to access the potential of these innovative CAR cells. This review aims to thoroughly examine the advantages, challenges, and existing insights on these new CAR products in cancer treatment.

show abstract